Intestinal Research

Laurent Peyrin-Biroulet

2 Articles

Inflammatory bowel diseases

Histologically confirmed upper gastrointestinal Crohn’s disease: is it rare or are we just not searching hard enough?: Omar Ibrahim Saadah, Kholoud Bakur Fallatah, Cedric Baumann, Abdulrahman Ahmed Elbaradie, Fatimah Talat Howladar, Motaz Tariq Daiwali, Omar Hamad Alshuaibi, Majid Abdulaziz Alsahafi, Rana Yaqoob Bokhary, Yousef Abdulfattah Qari, Laurent Peyrin-Biroulet, Mahmoud Hisham Mosli; Intest Res 2020;18(2):210-218. Published online February 7, 2020; DOI: https://doi.org/10.5217/ir.2019.00091

Background/Aims
Crohn’s disease (CD) may involve the upper parts of the gastrointestinal (GI) tract including the esophagus, stomach, and duodenum. Clinical features of upper GI CD (UGICD) are not well characterized in the Gulf region. We therefore aimed to assess the prevalence and clinical characteristics of patients diagnosed with UGICD.
Methods
We performed a retrospective analysis of all patients diagnosed with CD who underwent upper GI endoscopy between 2012 and 2017 at King Abdulaziz University Hospital, irrespective of age. Patients who had endoscopy of the upper GI tract at baseline and had histologically confirmed UGICD were included. Data on patients’ demographics, clinical characteristics, extraintestinal manifestations and complications were reviewed.
Results
We identified 78 CD patients who underwent upper GI endoscopy from our medical records. The mean age was 17.2±8.7 years and 55.1% were males. Of the total, 19 out of 78 patients (24.4%) had histologically confirmed UGICD (3 esophageal, 16 gastric, and 9 duodenal), of which 52.6% were symptomatic. Disease distribution was ileal in 57.8%, colonic in 21.1% and ileo-colonic in 21.1%. A non-stricturing and non-penetrating phenotype was reported in 89.4%, stricturing in 5.3%, and penetrating in 5.3%. Perianal disease was found in 10.5%. UGICD was complicated by stricture formation in 2 patients (esophageal and gastric).
Conclusions
The prevalence of UGICD is considered high among CD Saudi patients who undergo upper GI endoscopy at baseline, and is asymptomatic in 47.4% of patients. This reported prevalence is not dissimilar from reports originating from Western countries.

Citations

Citations to this article as recorded by

Les maladies inflammatoires chroniques intestinales (MICI) et tube digestif haut
Denis Chatelain, Amine Moslemi, Axel Dreau, Marine Clement
Annales de Pathologie.2023; 43(3): 192. CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef
A systematic review and meta‐analysis of prevalence and clinical features of upper gastrointestinal (UGI) tract Crohn's disease in adults compared to non‐UGI types
Babak Tamizifar, Peyman Adibi, Maryam Hadipour, Vahid Mohamadi
JGH Open.2023; 7(5): 325. CrossRef
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mahmoud H. Mosli, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Amr M. Khardaly, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baward
Saudi Journal of Gastroenterology.2023; 29(Suppl 1): S1. CrossRef
Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?
Naoimh Herlihy, Roger Feakins
United European Gastroenterology Journal.2022; 10(5): 451. CrossRef
Focal Active Brunner Gland Lobulitis: Ignored or Yet Undetected Sign of Crohn Duodenitis?
Badr AbdullGaffar, Huda Quarishi
Advances in Anatomic Pathology.2022;[Epub] CrossRef
Histopathologic Manifestations of Crohn Disease in Duodenal Endoscopy Biopsy: The Value of Different Patterns of Involvement of Brunner Glands
Badr AbdullGaffar, Hoda Quraishi
International Journal of Surgical Pathology.2021; 29(7): 710. CrossRef
“Is Focally Enhanced Active Inflammation of Brunner Glands a Sign of Crohn Duodenitis?”
Badr AbdullGaffar, Hoda Quraishi
International Journal of Surgical Pathology.2021; 29(8): 926. CrossRef
Systematic review with meta-analysis: The prevalence, risk factors and outcomes of upper gastrointestinal tract Crohn's disease
Yip Han Chin, Cheng Han Ng, Snow Yunni Lin, Sneha Rajiv Jain, Gwyneth Kong, Jeffery Wei Heng Koh, Darren Jun Hao Tan, David Eng Hui Ong, Mark Dhinesh Muthiah, Choon Seng Chong, Fung Joon Foo, Rupert Leong, Webber Pak Wo Chan
Digestive and Liver Disease.2021; 53(12): 1548. CrossRef
Non gastro-esophageal reflux disease related esophagitis: an overview with a histologic diagnostic approach
Luca Mastracci, Federica Grillo, Paola Parente, Elettra Unti, Serena Battista, Paola Spaggiari, Michela Campora, Luca Valle, Matteo Fassan, Roberto Fiocca
Pathologica.2020; 112(3): 128. CrossRef

7,793 View
169 Download
10 Web of Science
10 Crossref

IBD

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach: Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho; Intest Res 2018;16(4):522-528. Published online October 16, 2018; DOI: https://doi.org/10.5217/ir.2018.00073

Abstract PDF Supplementary Material PubReader ePub

Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare systems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatment when necessary. An international panel of experts produced consensus statements and recommendations. These were informed by evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria for second-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient to induce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonide MMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potential to improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place in the UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economic benefits.

Citations

Citations to this article as recorded by

Sodium orthovanadate protects against ulcerative colitis and associated liver damage in mice: insights into modulations of Nrf2/Keap1 and NF-κB pathways
Gurpreet Kaur, Ajay Singh Kushwah
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(2): 1557. CrossRef
Management and treatment optimization of patients with mild to moderate ulcerative colitis
Ferdinando D’Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Clinical Immunology.2024; 20(3): 277. CrossRef
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421. CrossRef
Framework of IBD Care Delivery Across Ages
Stefan Delen, Susanna Jaghult, Irina Blumenstein, Lieven Pouillon, Peter Bossuyt
Journal of Crohn's and Colitis.2024; 18(Supplement): ii55. CrossRef
Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
Yurianna Santos, Arturo P Jaramillo
Cureus.2023;[Epub] CrossRef
Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating
Huilong Luo, Feng Wu, Xinyue Wang, Sisi Lin, Mengmeng Zhang, Zhenping Cao, Jinyao Liu
Materials Today.2023; 62: 98. CrossRef
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Ferdinando D’Amico, Fernando Magro, Benedicte Caron, Axel Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2023; 12(3): 1142. CrossRef
A review article of inflammatory bowel disease treatment and pharmacogenomics
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
Scandinavian Journal of Gastroenterology.2022; 57(4): 424. CrossRef
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
Linde E. M. de Wijs, Sven van Egmond, Arjan C. A. Devillers, Tamar Nijsten, DirkJan Hijnen, Marjolein Lugtenberg
Archives of Dermatological Research.2022; 315(1): 75. CrossRef
Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis
M. V. Shapina
Meditsinskiy sovet = Medical Council.2022; (15): 90. CrossRef
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone
Therapeutics and Clinical Risk Management.2021; Volume 17: 285. CrossRef
High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324. CrossRef
The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis
Chunying Tian, Yang Huang, Xiaoxia Wu, Chuhan Xu, Huaien Bu, Hongwu Wang, Jairo Kennup Bastos
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef
Teleconsulta en la pandemia por Coronavirus: desafíos para la telemedicina pos-COVID-19
Juan Ricardo Márquez Velásquez
Revista Colombiana de Gastroenterología.2020; 35(Supl. 1): 5. CrossRef
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2020; 9(9): 2905. CrossRef
A clinical case of ulcerative colitis in a patient with viral hepatitis
E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
South Russian Journal of Therapeutic Practice.2020; 1(3): 95. CrossRef
Case Report on Ulcerative Colitis in 16 year girl
MD.Salma MD.Salma, Y.Siva Y.Siva , , J.Bhargava Narendra , J.Bhargava Narendra
World Journal of Current Medical and Pharmaceutical Research.2020; : 287. CrossRef

12,063 View
568 Download
16 Web of Science
18 Crossref

Author index